Reported 14 days ago
Eli Lilly and Novo Nordisk, leading companies in the weight-loss drug market, face challenges following disappointing third-quarter earnings, which revealed softening demand for their popular products. Although both companies reported significant revenue growth, they also trimmed their annual sales forecasts, indicating potential future growth may come with narrower profit margins. This situation suggests that while growth is not over, both firms may need to invest more in marketing and R&D to maintain their market positions as competition intensifies.
Source: YAHOO